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Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients 
have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label 
study compared the effects of once weekly alendronate 70 mg containing 5600 IU 
vit-D3 (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the 
percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary end-
point] and serum parathyroid hormone (PTH, secondary endpoint) levels in post-
menopausal, osteoporotic Korean women. Neuromuscular function was also mea-
sured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D 
insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D in-
sufficiency in the ALN/D5600 group (1.47%) than in the ALN group (41.67%) 
(p<0.001). Patients receiving ALN/D5600 compared with ALN were at a signifi-
cantly decreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence in-
terval (CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 
25(OH)D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as 
a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). 
By multiple regression analysis, major determinants of increases in serum 25(OH)
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cient levels of vitamin D.12,13 According to a recent study in 
Korea, the average serum 25-hydroxy-vitamin D [25(OH)D] 
level of Korean postmenopausal women was 17 ng/mL 
(values less than 15 ng/mL were considered insufficient 
when the current study was designed).15,16
Combination therapy with a drug and a vitamin supple-
ment is a useful method for treating vitamin insufficient os-
teoporotic patients. A single-tablet, once weekly formula-
tion of alendronate 70 mg plus vitamin D3 2800 IU (ALN/
D2800) was introduced to provide vitamin D3 to osteopo-
rotic patients. In a previous study, ALN/D2800 reduced the 
proportion of patients with 25(OH)D below 15 ng/mL by 
64% after 15 weeks of treatment.17 Subsequently, a higher 
5600 IU weekly dose of vitamin D3, (corresponding to 800 
IU daily) was recommended for some groups, including pa-
tients with osteoporosis or a sedentary life style and institu-
tionalized elderly.18,19
This 16-week, open-labeled, randomized, active con-
trolled study was conducted to directly compare the effica-
cy of the higher 5600 IU dose of vitamin D3 combined with 
weekly alendronate 70 mg to weekly alendronate 70 mg 
alone (without vitamin D3 supplements). Calcium carbon-
ate (500 mg/day) was also administered. The primary ob-
jective of this study was to evaluate the effects of treatment 
on vitamin D status as assessed by serum 25(OH)D levels, 
with the goal of reducing the risk of vitamin D insufficien-
cy. Examining the effect of treatment on parathyroid hor-
mone (PTH) levels was a secondary objective, and assess-
ment of the effects on neuromuscular function was an 
exploratory objective of the study. 
MATERIALS AND METHODS
　　　
Study subjects and design
This study was a prospective, 16-week, randomized, open-
labeled, active controlled trial conducted across 17 investi-
gational centers in Korea. Patients were recruited for the 
study beginning in March 2008, and by April 2009 the 
study was completed. Vitamin D insufficiency and vitamin 
D deficiency were defined as serum 25(OH)D level <15 ng/
mL and 25(OH)D <9 ng/mL, respectively. 
Inclusion in the study required satisfactory general 
health; being postmenopausal (≥6 months beyond the final 
menstrual period); serum 25(OH)D ≥9 ng/mL; presence of 
osteoporosis [defined as one of the following: lumbar spine 
or femoral neck T-score ≤-2.5, T-score ≤-2.0 with any lum-
D were ALN/D5600 administration, seasonal variation, and 
baseline 25(OH)D. The least squares mean percent change 
from baseline in serum PTH in the ALN/D5600 group 
(8.17%) was lower than that in the ALN group (29.98%) 
(p=0.0091). There was no significant difference between 
treatment groups in neuromuscular function. Overall safety 
was similar between groups. In conclusion, the administra-
tion of 5600 IU vit-D in the ALN/D5600 group improved 
vit-D status and reduced the magnitude of PTH increase 
without significant side-effects after 16 weeks in Korean 
osteoporotic patients.
Key Words:   Alendronate, vitamin-D, vitamin-D insuffi-
ciency, osteoporosis, parathyroid hormone
INTRODUCTION
Osteoporosis, the most common bone disorder in post-
menopausal women, is characterized by reduced bone den-
sity, increased bone turnover, and micro-structural abnor-
malities that lead to increased fracture risk morbidity and 
mortality.1,2 Approximately 75 million people worldwide 
have osteoporosis, including one-third of postmenopausal 
women and the great majority of the elderly,2 and the prev-
alence of osteoporosis and its socio-economic burden are 
expected to increase due to increasing average life expectan-
cy.3 The disease burden of osteoporosis is a growing con-
cern in many countries, including Korea,4-6 where among 
women 40-79 years of age, the prevalence of osteoporosis 
is approximately 30%.7 
Vitamin D is an important component of osteoporosis 
treatment,8 both for its direct effects on bone and the fact 
that optimal vitamin D nutrition appears to maximize the 
response to anti-resorptive agents in vitamin D insufficient 
patients.9,10 In addition to its effects on bone, vitamin D de-
ficiency is also associated with insulin resistance, metabolic 
syndrome, vitamin D supplementation improved muscle 
strength, physical performance and decreased risk of falls.11-13 
Vitamin D is synthesized upon exposure to sunlight, and is 
absorbed from food. However, its synthesis is frequently 
insufficient and intake from un-supplemented food may be 
inadequate.8,14 Supplementation with cholecalciferol (vita-
min D3) is a practical and effective method of improving vi-
tamin D status. Unfortunately, even though such doses of 
vitamin D are recommended to osteoporotic women, many 
patients being treated for osteoporosis do not receive suffi-
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if he or she stopped taking calcium due to poor tolerance. If 
a patient’s 25(OH)D declined to <9 ng/mL, the central lab-
oratory notified the study site and the patient was with-
drawn from the study drug and treated with cholecalciferol 
within 2 weeks of the date of sample acquisition. Patients 
were not permitted to take supplemental vitamin D or calci-
um other than what was provided. The study was conduct-
ed in accordance with principles of Good Clinical Practice 
and was approved by the appropriate Institutional Review 
Boards and regulatory agencies. Written informed consent 
was obtained from all patients before performing any study 
procedure. 
Efficacy
The efficacy of the study drug was evaluated in patients who 
received at least one dose of investigational product and un-
derwent baseline and at least one efficacy measurement. The 
primary endpoint was serum 25(OH)D level, with the prima-
ry efficacy variable defined as the percentage of subjects with 
vitamin D insufficiency [serum 25(OH)D level <15 ng/mL]. 
Serum 25(OH)D (mean of duplicate measures) was mea-
sured prior to randomization and at weeks 8 and 16. The sec-
ondary efficacy variable was percentage change from base-
line in serum PTH. Serum PTH (mean of duplicate measures) 
was measured prior to randomization, and at week 16. For 
assessment of the exploratory endpoint, neuromuscular func-
tion was evaluated at five of the 17 investigational sites using 
tests of standing balance (examining ability to stand with the 
feet together in the side-by-side, semi-tandem, and tandem 
positions), gait speed (8-foot walk test; the time of the faster 
of two trials was used for scoring), and time to rise from a 
chair five times (sit-to-stand test). Higher scores represent 
better function. The physical performance tests used in this 
study were previously described in detail.20,21
Safety
Clinical evaluations and laboratory measurements, includ-
ing serum chemistry and hematology were performed at se-
lected visits. All clinical and laboratory adverse experiences 
and concomitant medication use were recorded. The inves-
tigators evaluated and recorded all adverse experiences 
(AEs) based on predefined criteria regarding intensity, seri-
ousness, duration, action taken, and causal relationship with 
the investigational drug.
Safety and tolerance were evaluated by reviewing all safe-
ty variables including clinical adverse experiences, labora-
tory test results, and vital signs. Serious AEs were immedi-
bar spine fracture, or two or more fractures in lumbar spine 
regardless of bone mineral density (BMD)]; no contraindica-
tion to oral bisphosphonates; spine or hip anatomy suitable 
for dual-energy X-ray absorptiometry (DXA); willingness to 
limit direct sunlight exposure to <1 hour/day with sunscreen; 
and avoidance of other vitamin D supplements during the 16-
week study. Patients with serum 25(OH)D levels <15 ng/mL 
but ≥9 ng/mL were required to have serum PTH and total al-
kaline phosphatase within reference ranges.
Reasons for exclusion included vitamin D deficiency 
[25(OH)D <9 ng/mL], abnormalities of the esophagus that 
delay esophageal emptying (e.g., stenosis or achalasia), cer-
tain malignancies, active systemic diseases that could pose 
an added risk to the patient or the patient’s ability to com-
plete the study, other disorders of bone or mineral metabo-
lism, or recent treatment with agents that affect bone or cal-
cium metabolism. Patients who could not sit or stand for at 
least 30 minutes and patients with a history of alcohol or 
drug abuse were also excluded. 
Patients were evaluated for eligibility at a screening visit 
(day -14--day -1), followed by a randomization visit (week 
0); two additional clinic visits (weeks 8 and 16), during 
which compliance and adverse experiences were assessed; 
and one follow up visit or telephone contact (week 18) to 
assess adverse experiences. Patients were allocated to treat-
ment groups using a computer-generated randomized allo-
cation schedule created by the study’s statistician. Num-
bered containers were used to implement allocation, and 
each patient was assigned the next number in the sequence 
upon being enrolled.
Treatment
Patients were randomly assigned to receive once-weekly 
tablets containing either ALN/D5600 or ALN, both manu-
factured by Merck & Co., Inc., Whitehouse Station, NJ, 
USA. Patients were instructed to take tablets in a fasting 
state upon waking up in the morning a half-hour before the 
first food, beverage (except water), or other medication. 
They were also told to stay upright until consuming the first 
food of the day. Patients recorded doses of study medication 
taken or missed in a diary that was brought to each clinic 
visit. Both ALN/D5600- and ALN-treated groups were giv-
en 500 mg/day of calcium carbonate (200 mg of elemental 
calcium), to be taken at least 30 minutes after ingestion of 
the ALN/D5600 or ALN tablet. If a subject showed poor 
tolerance to the calcium carbonate, calcium citrate could be 
prescribed. The subject was not withdrawn from the study 
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weighted average of Cochran-Mantel-Haenszel in which 
pre-treatment vitamin D level was adjusted. The secondary 
efficacy evaluation variable, % change of PTH at 16 weeks, 
was analyzed by analysis of covariance, with baseline se-
rum PTH level as the covariate. Treatment effects on neuro-
muscular function were evaluated by the chi-square or Fish-
er’s exact test. 
Missing data for the efficacy evaluation were imputed by 
the last observation carried forward technique.
RESULTS
 
A total of 343 subjects who met eligibility criteria were ran-
domly allocated (173 in the ALN/D5600 group and 170 in 
the ALN group). Patient disposition is shown in Fig. 1. The 
Modified Intend-to-treat set for efficacy evaluation consist-
ed of 268 (136 in ALN/D5600 group and 132 in ALN group) 
subjects who received at least one dose of investigational 
product and who underwent efficacy assessment of a pre-
treatment value and at least one value after the start of treat-
ment. Subject data were analyzed based on the allocated 
treatment group at randomization regardless of the drugs 
administered during the trial. The safety evaluation utilized 
the all patients as treated set for 341 subjects (171 for ALN/
D5600 and 170 for ALN) who received drugs at least once 
after randomization. They were analyzed according to the 
drugs actually administered. 
Demographic and other baseline characteristics
There were no clinically meaningful differences between 
the groups at baseline (Table 1). In both treatment groups, 
the largest age group was between 60 and 69 years. The 
mean elapsed time since diagnosis of osteoporosis was ap-
proximately 2 years for each treatment group, although most 
patients were not previously treated for osteoporosis (Table 
1). The number of subjects who had ever taken vitamin D 
was similar between the two groups and was not statistical-
ly significant (n=7 in ALN/D5600 vs. n=3 in ALN group). 
The proportion of subjects with vitamin D insufficiency in 
the treatment groups was not significantly different at base-
line (Table 2). 
Measurements of treatment compliance
The mean compliance of study drug treatment was 98.44± 
7.64% in the ALD/D5600 group and 98.86±4.93% in the 
ALN group. The two groups did not show a statistically 
ately reported to MSD Korea regardless of the investigator’s 
assessment of a causal relationship to study drug, and were 
recorded for each subject.
Clinical measurements
Serum 25(OH)D was analyzed by radioimmunoassay (RIA) 
(DiaSorin Inc., Stillwater, MN, USA; the company citing a 
2× standard deviation range in their reference group of 9.0-
37.6 ng/mL). Serum PTH was analyzed by immunoradiomet-
ric assay using ELSA-PTH (CIS Bio International, Sorgues, 
France, the normal reference range cited by the manufac-
turer being 8-76 pg/mL). Serum calcium, phosphorus, blood 
urea nitrogen, creatinine, alkaline phosphatase, aspartate ami-
notransferase, and alanine aminotransferase were assessed at 
each site. 
BMD of the spine (L1, L2, L3, and L4) and femur (fem-
oral neck and femur total) was assessed by DXA (Hologic- 
Hologic Corporation, Waltham, MA, USA or GE Lunar- 
GE Healthcare Lunar, Madison, WI, USA). 
Statistical analysis
Patients were stratified according to baseline 25(OH)D: a 
vitamin D insufficient group [25(OH)D <15 ng/mL] and a 
vitamin D sufficient group [25(OH)D ≥15 ng/mL]. The 
type I error was 0.025 (one-sided) and the power was 90% 
to detect a 0.375 odds ratio of vitamin D insufficiency be-
tween ALN/D5600 and ALN groups with 175 patients ran-
domized into each treatment group. This calculation was 
based on an overall dropout rate of 20% from the beginning 
of the study (i.e., n=140 per group).
The differences in the ratios between treatment groups 
for the analysis of primary efficacy evaluation variables and 
95% confidence intervals (CI) were calculated using the 
Fig. 1. Summary of patient disposition.
Screened (n=644)
Randomized (n=343)
No study medication taken (n=2)
Enrolled prior to contract (n=1)
Violation of inclusion/exclusion criteria 
  (n=48)
Medication error (n=3)
No efficacy measurements (n=21)
Alendronate 70 mg+Vit D3, 
5600 IU weekly (n=173)
Completed (n=136)
Alendronate 70 mg
weekly (n=170)
Completed (n=132)
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serum 25(OH)D] at week 8 was 9.60 ng/mL in the ALN/
D5600 group, but was -0.81 ng/mL in the ALN group, a 
significant difference between the groups (p<0.001). The 
mean change from baseline in serum 25(OH)D at 16 weeks 
was 11.41 ng/mL in the ALN/D5600 group, while it was 
-1.61 ng/mL in the ALN group (p<0.001 between groups). 
Increases in serum 25(OH)D were much higher in sub-
groups that were vitamin D-insufficient at baseline, com-
pared with those vitamin D-sufficient at baseline, in both 
significant difference in treatment compliance (p=0.589).
 
Primary endpoint: serum 25-hydroxyvitamin D
As shown in Table 2, mean serum 25(OH)D increased at 
weeks 8 and 16 from baseline in the ALN/D5600 group (p 
<0.001). However, in the ALN group, mean values of se-
rum 25(OH)D decreased from baseline at weeks 8 and 16, 
with the decline reaching significance at week 16 (p<0.01). 
The mean change in serum 25(OH)D [adjusted for baseline 
Table 1. Baseline Characteristics of Patients by Treatment Group
Characteristics ALN/D5600 (n=136) ALN (n=132) Total (n=268) p value
Age (yrs) 64.92±6.88 65.57±7.82 65.24±7.35 0.4712*
Age of sub-group
    50-59   35 (25.74)   33 (25.00)   68 (25.37) 0.3073‡
    60-69   68 (50.00)   54 (40.91) 122 (45.52)
    70-79   31 (22.79)   42 (31.82)   73 (27.24)
    ≥80   2 (1.47)   3 (2.27)   5 (1.87)
Height (cm) 152.4±5.85 152.47±5.57 152.43±5.70 0.9208*
Weight (kg) 54.27±6.79   55.18±7.02   54.72±6.91 0.2861*
SBP (mm Hg) 122.76±14.16   123.67±13.63   123.21±13.88 0.5945*
DBP (mm Hg)   72.2±8.18   73.56±8.82   72.87±8.51 0.1927*
Serum 25(OH)D (ng/mL) 18.60±6.48   18.83±6.54   18.71±6.50 0.7710*
Serum PTH (pg/mL)   25.25±10.69     23.37±11.23     24.33±10.98 0.1605*
Season at screening  0.8771†
    Spring  (Mar.-May)   38 (27.94)   40 (30.30)   78 (29.10)
    Summer (Jun.-Aug.)   75 (55.15)   72 (54.55) 147 (54.85)
    Autumn (Sep.-Nov.)   23 (16.91)   20 (15.15)   43 (16.04)
Osteoporosis treatment history
    No 101 (74.26) 105 (79.55) 206 (76.87) 0.3054†
    Yes   35 (25.74)   27 (20.45)   62 (23.13)
ALN/D5600, alendronate containing 5600 IU of vitamin D3; ALN, alendronate; SBP, systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D, serum 
25-hydroxy-vitamin D; PTH, parathyroid hormone.
Data are expressed as number (percentage) or as mean±SD. Missing in control group (N): height (2), weight (2), SBP (1), DBP (1). 
*Unpaired t-test.
†Chi-square test.
‡Fisher’s exact test.
Table 2. Mean Values of 25(OH)D 
Group
Baseline Wk 8 Wk 16
n Mean±SD n Mean±SD n Mean±SD
ALD/D5600 
    Vit D insufficiency at baseline   49 12.28±1.46   46 26.70±5.56†   49 28.84±6.77†
    Vit D non-insufficiency at baseline   87 22.15±5.39   87 29.22±4.52†   87 30.77±5.22†
    Total 136 18.60±6.48 133 28.35±5.03† 136 30.08±5.87†
ALN
    Vit D insufficiency at baseline   44 12.35±1.88   43  15.49±5.54*   44  14.84±4.99*
    Vit D non-insufficiency at baseline   88 22.07±5.55   86  19.24±5.02†   88 18.29±6.21†
    Total 132 18.83±6.54 129 17.99±5.47 132  17.14±6.04*
ALN/D5600, alendronate containing 5600 IU of vitamin D3; ALN, alendronate; Vit D, vitamin D.
Vitamin D insufficiency [Yes: 25(OH)D <15 ng/mL, No: 25(OH)D ≥15 ng/mL]. 
*p<0.01, †p<0.0001 compared to values of baseline.
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tamin D insufficiency at week 16 (Supplementary Table 1, 
only online). 
In multiple regression analysis, major determinants of 
delta increment of serum 25(OH)D were ALN/D5600 ad-
ministration, basal 25(OH)D level, and seasonal variation 
(Supplementary Table 2, only online).
Secondary endpoint: PTH 
The percent change from baseline in serum PTH at week 
16 was analyzed as a secondary endpoint (Supplementary 
Table 3, only online) (Fig. 3). In the ALN/D5600 group, a 
small and non-significant increase from baseline to week 
16 was observed, whereas a significant increase (p<0.001) 
was observed in the ALN group. The least squares mean 
percent change from baseline of serum PTH in the ALN/
D5600 group was significantly lower than that in the ALN 
group (8.17% vs. 29.98%, respectively, p<0.01).
 
Exploratory endpoint: neuromuscular function 
There were no significant differences in test results of neu-
romuscular function between the treatment groups (Fig. 4).
Safety and adverse events evaluation
A similar percentage of participants reported clinical AEs (in-
treatment groups (Fig. 2).
Table 3 describes the proportion of subjects with vitamin 
D <15 ng/mL at week 8 and week 16 in each treatment 
group. The percentage of subjects with vitamin D insuffi-
ciency at week 8 was 0.75% (n=1/133) in the ALN/D5600 
group and 28.68% (n=37/129) in the ALN group, and the 
difference between the groups was statistically significant 
(p<0.001). At week 16, the percentage with vitamin D insuf-
ficiency was 1.47% (n=2/136) in the ALN/D5600 group and 
41.67% (n=55/132) in the ALN group (p<0.001). The odds 
ratio of vitamin D insufficiency in the ALN/D5600 group 
was significantly lower than that in the ALN group after 8 
(odds ratio=0.01, 95% CI 0.00-0.08) and 16 weeks of treat-
ment (odds ratio=0.02, 95% CI 0.00-0.08).
Among patients with 25(OH)D levels <15 ng/mL at base-
line, the proportions of persisting insufficiency were 2.17% 
(n=1/46) at week 8 and 4.08% (n=2/49) at week 16 in the 
ALN/D5600 group. However, they were 53.49% (n=23/43) 
at week 8 and 52.27% (n=23/44) at week 16 in the ALN 
group. In the ALN/D5600 group, there was no incidence of 
newly developed vitamin D insufficiency in patients with 
vitamin D sufficiency at baseline either at week 8 or week 
16. In contrast, 36.36% (n=32/88) of subjects in the ALN 
group with vitamin D sufficiency at baseline developed vi-
Fig. 2. Mean change of 25-hydroxyvitamin D according to baseline 25-hydroxyvitamin D status. (A) Mean change of 25-hydroxyvitamin D in patients receiv-
ing alendronate containing 5600 IU of vitamin D3. (B) Mean change of 25-hydroxyvitamin D in patients receiving alendronate. ALN, alendronate.
Table 3. Proportion of Patients with Vitamin D Insufficiency at Baseline, Week 8 and Week 16
 Vitamin D 
  insufficiency in   
  post-treatment
Wk 8 Wk 16
ALN/D5600 
(n=136)
ALN 
(n=132)
Total 
(n=268)
Difference 
[95% CI]
ALN/D5600 
(n=136)
ALN 
(n=132)
Total 
(n=268)
Difference 
[95% CI]
Yes, n (%)   1 (0.75) 37 (28.68)   38 (14.50) -27.93† [-35.87~ 
-19.99]
  2 (1.47) 55 (41.67)   57 (21.27) -40.20† [-48.85~ 
-31.55]No, n (%) 132 (99.25) 92 (71.32) 224 (85.50) 134 (98.53) 77 (58.33) 211 (78.73)
ALN/D5600, alendronate containing 5600 IU of vitamin D3; ALN, alendronate; CI, confidence interval.
Vitamin D insufficiency [Yes: 25(OH)D <15 ng/mL, No: 25(OH)D ≥15 ng/mL]. Cochran-Mantel-Haenszel test using covariate as vitamin D deficiency at base-
line. Missing data at week 8-ALN/D5600 (3 subjects), ALN (3 subjects).
†p<0.0001.
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ponent in maintaining bone mass and reducing fracture risk. 
Without adequate vitamin D, the body cannot produce the 
active hormone calcitriol (1,25-dihydroxyvitamin D), whose 
principal action is to enhance intestinal calcium and phos-
phate absorption. Therefore, disorders of bone formation 
and resorption (i.e., osteomalacia and osteoporosis) may be 
associated with lack of vitamin D. In addition, vitamin D is 
also involved in other aspects of bone formation and resorp-
tion. The vitamin D receptor is expressed in endocrine cells, 
muscle cells, and immune cells, including macrophages and 
bone cells,22-24 and vitamin D deficiency may also be asso-
ciated with some non-bone effects, including hypertension, 
and chronic infections such as tuberculosis.8,14 Vitamin D 
insufficiency is a worldwide problem.17 Recent meta-analy-
sis revealed that vitamin D intake less than 700 IU/day was 
not sufficient for prevention of fractures.11,12 
A total of 343 volunteers participated in this randomized 
clinical trial, and the average basal serum 25(OH)D concen-
tration was 18.7 ng/mL, a value comparable to previously re-
ported values in Korean population.15 As expected, compared 
to ALN once weekly alone, the addition of 5600 units of vi-
tamin D3 in ALN/D5600 once weekly for 16 weeks signifi-
cantly increased serum 25(OH)D concentration (ALN/ 
D5600 once weekly: 18.6 to 30.1 ng/mL vs. ALN alone: 
18.8 to 17.1 ng/mL). In fact, serum 25(OH)D concentrations 
obtained at 8 weeks after ALN/D5600 once weekly adminis-
tration reached approximately 94% of the level at 16 weeks. 
Just 8 weeks of treatment with ALN/D5600 was enough to 
increase the mean serum 25(OH)D level close to a level that 
has been argued by some to be optimal (>30 ng/mL).13
To evaluate the effect of ALN/D5600 on serum 25(OH)D 
concentration according to basal serum 25(OH)D levels, 
subjects were grouped according to baseline 25(OH) levels 
cluded regardless of the investigator’s assessment of causal 
relationship to study drug): 37.43% (n=64/171, 105 cases) 
in the ALN/D5600 group and 32.35% (n=55/170, 87 cases) 
in the ALN group (Table 4). Serious AEs reported during 
the study period comprised 4.09% (n=7/171, 10 cases) in 
the ALN/D5600 group and 0.59% (n=1/170, 1 case) in the 
ALN group. Among 10 cases in the ALN/D5600 group (lung 
abscess, uterine prolapse, cystocele, gastric tumor, stroke, flu-
like symptom, otitis media, and herpes zoster), only 1 case 
(flu-like symptom) was considered a drug related adverse 
event. The severity of the serious adverse drug reactions 
was mild, not life-threatening, and did not require hospital-
ization. AEs determined by the investigator to be related to 
study drug comprised 15.20% (n=26/171, 34 cases) in the 
ALN/D5600 group and 14.71% (n=25/170, 33 cases) in the 
ALN group. There were no statistically significant differ-
ences in incidence of adverse events and adverse drug reac-
tions between the groups.
DISCUSSION
This is the first study to evaluate a fixed dose combination of 
alendronate 70 mg with and without cholecalciferol 5600 IU 
in Korean postmenopausal women with osteoporosis. This 
study showed that, compared with ALN alone, once-weekly 
ALN/D5600 provided superior efficacy for increasing serum 
25(OH)D levels, reduced the risk of vitamin D insufficiency, 
and reduced the magnitude of the PTH increase significantly 
in patients with osteoporosis. The relative safety and tolera-
bility of the 5600 IU vitamin D present in alendronate plus D 
5600 were also demonstrated in this study. 
In osteoporosis treatment, vitamin D is an essential com-
Fig. 3. Percent change from baseline in serum PTH at 16 weeks. *p<0.01 
between treatments. PTH, parathyroid hormone; ALN, alendronate.
Fig. 4. Neuromuscular Function Tests at 16 Weeks. *Fisher’s exact test, 
**Chi-square test. ALN, alendronate.
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vs. 40/112). We did not find any effects of age regardless of 
the basal 25(OH)D levels (data not shown). 
ALN is a powerful anti-resorptive agent, and it inhibits 
the bone resorbing activity of osteoclasts by competitively 
inhibiting farnesyl pyrophosphatase; it also induces apopto-
sis of osteoclasts in very high doses, but the drug produces 
a reversible inhibition of osteoclast function at doses typi-
cally used to treat osteoporosis.26,27 Previous studies report-
ed that ALN treatment increases serum PTH by reducing 
bone resorption and slightly reducing serum calcium.27 Con-
tinuous elevation of serum PTH is reported to be detrimen-
tal to non-osseous tissues and may promote catabolic ef-
fects on bone.28,29 On the other hand, ALN/D5600 once 
weekly increased serum 25(OH)D without any meaningful 
increase in serum PTH. This observation may answer the 
question why PTH increases when bisphosphonates are 
started. While the primary effect on PTH is from reduction 
with a cutoff value of 15 ng/mL. Interestingly, compared to 
the vitamin D-sufficient group, increases in serum 25(OH)D 
were greater in the vitamin D-insufficient group after thera-
py (16.5 ng/mL vs. 8.6 ng/mL). We obtained similar results 
even after adjusting the cutoff value of vitamin D insufficien-
cy to 10 ng/mL or 20 ng/mL (data not shown). A previous 
study reported that larger increases in 25(OH)D were typical-
ly observed in patients with very low baseline 25(OH)D, 
probably due to the fact that production of 25(OH)D is regu-
lated with greater expression of 25-hydroxylase at low 
25(OH)D levels and more conversion of 25(OH)D to 
24,25(OH)2D at higher levels of 25(OH)D.25 
In our multiple regression analysis, basal 25(OH)D, sea-
sonal variation, and ALN/D5600 once weekly were identi-
fied as the most important factors influencing the observed 
increases in 25(OH)D level. Similar numbers of subjects in 
both groups were recruited in the spring and summer (45/113 
Table 4. Clinical Adverse Experiences (Regardless of Investigator’s Assessment of Causal Relationship to Study Drug) Classi-
fied by System Organ Class (APaT Set); Preferred Term with Incidence ≥1% Are Included 
System organ class/Preferred term*
Number of subjects (%)
ALN/D5600 (n=171) ALN (n=170)
Any AE   64 (37.43)   55 (32.35)
    Gastrointestinal disorders   21 (12.28)   23 (13.53)
        Dyspepsia 11 (6.43)   18 (10.59)
        Nausea   3 (1.75)   1 (0.59)
        Vomiting   3 (1.75)   0 (0.00)
        Epigastric discomfort   2 (1.17)   3 (1.76)
    Musculoskeletal and connective tissue disorders   20 (11.70)   23 (13.53)
        Myalgia   8 (4.68) 11 (6.47)
        Back pain   6 (3.51)   1 (0.59)
        Arthralgia   4 (2.34)   3 (1.76)
        Musculoskeletal pain   1 (0.58)   3 (1.76)
    Infections and infestations 13 (7.60) 11 (6.47)
        Nasopharyngitis   8 (4.68)   8 (4.71)
        Cystitis   2 (1.17)   0 (0.00)
        Upper respiratory tract infection   0 (0.00)   3 (1.76)
    General disorders and administration site conditions   6 (3.51)   6 (3.53)
        Asthenia   2 (1.17)   0 (0.00)
        Chest discomfort   2 (1.17)   2 (1.18)
        Chills   2 (1.17)   0 (0.00)
    Nervous system disorders   7 (4.09)   4 (2.35)
        Headache   4 (2.34)   2 (1.18)
        Dizziness   2 (1.17)   2 (1.18)
    Skin and subcutaneous tissue disorders   3 (1.75)   4 (2.35)
        Pruritus   3 (1.75)   1 (0.59)
        Urticaria   0 (0.00)   2 (1.18)
    Cardiac disorder   2 (1.17)   0 (0.00)
        Palpitations   2 (1.17)   0 (0.00)
APaT, all patients as treated; ALN/D5600, alendronate containing 5600 IU of vitamin D3; ALN, alendronate.
*Overlap count.
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